The DNA binding domain (DBD) of poly(ADP-ribose) polymerase (PARP) has proved to be a novel, highly sensitive probe for detecting DNA breaks in intact cells undergoing apoptosis. A recombinant peptide spanning the DNA binding domain of PARP was expressed, purified and used to detect DNA strand breaks in fixed cells. Fluorescence microscopy with this probe followed by detection with anti-PARP antisera initially revealed an increased binding following treatment of cells with DNA strand-breaking agents (such as N-methyl-N′-nitro-N-nitrosoguanidine) and, subsequently, using biotinylated PARP DBD, during the later stages of apoptosis in several cell systems, when internucleosomal strand breaks became evident. This procedure was found to be at least as sensitive and required fewer steps to detect DNA strand breaks than those utilizing Klenow incorporation of biotinylated nucleotides.
INTRODUCTION
Poly(ADP-ribose) polymerase (PARP) is an abundant nuclear protein that is associated with chromatin. This enzyme covalently attaches to and elongates homopolymers of poly(ADP-ribose) to a number of nuclear proteins, using NAD, an abundant nucleotide in eukaryotic nuclei, as substrate. PARP is a zinc finger-containing protein, allowing the enzyme to bind to either double-or single-strand DNA breaks without any apparent sequence preference. Cell culture systems have demonstrated that PARP is involved in numerous biological functions, all of which are associated with the breaking and rejoining of DNA strands (1) (2) (3) (4) (5) (6) . The enzyme has an absolute requirement for DNA for activity and is activated proportionately by the number of strand breaks in DNA. We recently demonstrated that one of the earliest stages of apoptosis is characterized by activation of PARP and poly(ADPribose) addition to nuclear proteins during the reversible stages of apoptosis (7) and specific proteolysis of PARP has now been closely associated with a later stage of programed cell death (8) (9) (10) . This process occurs in a variety of cell types during organogenesis and during maturation of the immune system. During apoptosis, clumps of heterochromatin form adjacent to the nuclear matrix, nuclear fragmentation occurs and, ultimately, membrane-enclosed apoptotic bodies appear. These changes are accompanied by an increase in intracellular free Ca 2+ concentration. Increasing amounts of DNA strand breaks also occur during apoptosis. The first strand breaks that are associated with DNA cleavage at chromatin loops yield DNA fragment sizes >200 kb and can only be visualized by pulsed field electrophoresis. This is the stage that corresponds with activation of PARP (7) . Later in apoptosis, a specific Ca 2+ /Mg 2+ -dependent nuclease is activated that cleaves DNA in the linker region between nucleosomes, yielding a characteristic nucleosome ladder when the chromosomal DNA is analyzed by agarose gel electrophoresis.
Visualization at the level of individual cells allows for the assay of apoptosis. At the single cell level, the study of apoptosis requires morphological examination of cells and nuclei, using chromatin-and DNA-specific fluorescent dyes, such as ethidium bromide, bis-benzamide and 4′,6-diamidino-2-phenylindole. At the biochemical level, DNA breaks have been detected in situ utilizing the free 3′-OH ends of DNA as a substrate for either terminal transferase or the Klenow fragment of DNA polymerase I to incorporate biotin or digoxigenin, which can be subsequently visualized with either visible or fluorescent dyes.
Proteolytic cleavage of PARP was first demonstrated in chemotherapy-induced apoptosis (11) , where it was shown that PARP was processed into 85 and 24 kDa fragments. The 85 kDa fragment contains the catalytic and automodification domains, while the 24 kDa region consists of the DNA binding domain (DBD) of the enzyme. We recently explored the significance of PARP cleavage in the osteosarcoma cell model of apoptosis by examining the various participants in this specific aspect of programed cell death by immunofluorescence in whole cells (7) . In doing so, we recognized the potential to utilize the unique aspect of the PARP DNA binding domain as a direct indicator of DNA strand breaks that occur during apoptosis, as well as those that occur following DNA damage induced by alkylation. Accordingly, the experimental validity and general characterization of this new marker of apoptosis are described in detail below.
MATERIALS AND METHODS

Cells
Human osteosarcoma cells (American Type Culture Collection no. 11226) were cultured and apoptosis was induced as described previously (9) . Burkitt lymphoma cell line BL-30 (12) and EBV-induced lymphoblastoid cell line YB-26 were maintained (13) and induced to undergo apoptosis (14, 15) .
Expression, purification, renaturation and biotinylation of the recombinant PARP DBD
The PARP DBD fusion protein was expressed in Escherichia coli (as described in detail in Results) and purified to >95% homogeneity in a single step by Ni resin column chromatography (Qiagen). Bacterial cell lysate was loaded onto a Ni-NTA column pre-equilibrated in buffer A (10 mM Tris-HCl, pH 8.0, 1% NP-40, 10 mM 2-mercaptoethanol, 6 M guanidine-HCl). After the column was washed extensively in buffer A, buffer B (containing 8 M urea instead of guanidine-HCl) and buffer C (buffer B adjusted to pH 6.3), recombinant protein was eluted with buffer D (buffer B adjusted to pH 5.7). Fractions were then collected and analyzed by SDS-PAGE. SDS-PAGE revealed the size of the fusion protein to be ∼30 kDa, consistent with the predicted molecular mass of the PARP DBD attached to six histidine residues. PARP DBD protein was subsequently renatured by dialysis against seven changes of dialysis buffer (50 mM NaCl, 0.5 mM ZnCl 2 and 10 mM MgCl 2 in 50 mM phosphate buffer, pH 7.2) containing decreasing concentrations of urea (6, 4, 2 and 1 M), followed by decreasing concentrations of NaCl (1 M and 100 mM). Biotin labeling of PARP DBD was performed by incubating 5 µl biotin (long arm) N-hydroxysuccinimide ester in dimethylsulfoxide (5 mg/ml) with 250 µl PARP DBD (1 µg/µl) for 2 h at room temperature. The reaction was terminated with 5 mg glycine and the biotinylated PARP DBD protein was then dialyzed against 50 mM HEPES, pH 7.2, 20 mM ZnCl 2 , 100 mM NaCl and 70 µl 2-mercaptoethanol.
Immunofluorescence and immunoblot analysis
Antibodies to PARP DBD were derived by immunization of rabbits with a peptide corresponding to amino acids 25-41 of human PARP. Fixation of cells, immunofluorescence and immunoblot analysis were performed as previously described (7, 16) .
Detection of DNA fragmentation
DNA breaks were detected in situ using a Klenow fragment-based assay system (TACS1; Trevigen). Cells were fixed and labeled with biotinylated nucleotides, using streptavidin-conjugated horseradish peroxidase and diaminobenzidine for detection. Cells were counterstained with methyl green. Brown nuclei were positive for Klenow labeling. DNA nucleosome ladders were observed by isolation of total genomic DNA and agarose gel electrophoresis as described previously (9) .
PARP cleavage assay
Cytosolic extracts were prepared from cultured human osteosarcoma cells by homogenizing phosphate-buffered saline (PBS) washed cell pellets in 10 mM HEPES-KOH, pH 7.4, 2 mM EDTA, 0.1% (w,v) CHAPS, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml pepstatin A, 20 µg/ml leupeptin, 10 µg/ml aprotinin (at 1 × 10 8 cells/ml) and collecting the post-100 000 g supernatant. Assays contained 10 µg protein from the cytosol fractions of osteosarcoma cells derived from days 2 and 8 with purified [ 35 S]PARP (∼5 × 10 4 c.p.m.), 50 mM PIPES-KOH, 2 mM EDTA, 0.1% (w/v) CHAPS and 5 mM dithiothreitol in a volume of 25 µl. Incubations were performed at 37_C for 1 h and terminated by the addition of 25 µl 2× SDS-PAGE sample buffer containing 4% SDS, 4% β-mercaptoethanol, 10% glycerol, 0.125 M Tris-HCl, pH 6.8 and 0.02% bromophenol blue. Samples were analyzed by SDS-PAGE and fluorography.
RESULTS
Development of a new cytochemical assay for apoptotic DNA strand breaks based on a recombinant PARP cleavage product
Many of the currently available methods for examining DNA strand breaks in situ rely on the ability of exogenous enzymes such as DNA polymerase or terminal transferase to add labeled dNTPs to the 3′-OH ends of the strand breaks and subsequent detection of the incorporated nucleotides by immunofluorescence microscopy. We reasoned that the DBD of PARP might provide a more sensitive probe for DNA strand breaks that would eliminate the requirement for the often labile enzymes and nucleotide substrates.
Clone pCD12, containing the full-length cDNA encoding human PARP in an Okayama-Berg vector (17) , was used as a polymerase chain reaction (PCR) template for construction of a PARP DBD expression vector. PCR was performed with: (i) a 28 bp primer that contained a BamHI restriction site upstream (nt 164-180) of PARP cDNA; (ii) a 22 bp primer that contained a HindIII restriction site downstream (nt 837-854) of PARP cDNA. The PARP cDNA fragment thus amplified encompassed the region that encodes the two zinc fingers of the enzyme as well as the KKKSKK nuclear localization signal. Amplification was performed for 21 cycles and the product was then ligated into the bacterial protein expression vector pQE30 (Qiagen).
The DBD of PARP was subsequently expressed in E.coli and purified to >95% homogeneity by affinity chromatography using a Ni-NTA column (Fig. 1) . The PARP DBD fusion protein was recognized on immunoblot analysis by polyclonal antibodies, obtained subsequently, to this region of PARP (7). The double bands of the PARP DBD shown in the Coomassie stained gel in Figure 1 may be due to premature termination of transcription or translation, although both of these proteins reacted specifically to antibodies to PARP DBD (not shown). To establish conditions for detecting DNA strand breaks in fixed mouse cells with the PARP DBD, we first adopted an immunofluorescence approach using anti-human PARP. The antibody used does not react with the murine PARP (18) , even though the amino acid sequences of the proteins are >80% identical (17, 19) . We therefore incubated mouse 3T3 cells for 30 min in the absence or presence of 0.4 mM N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) to induce a significant number of DNA breaks, after which the cells were fixed on slides, incubated at room temperature with excess purified PARP DBD (25 µg/ml) for 1 h and washed with PBS. DBD bound to DNA strand breaks was then detected by incubating the slides with the rabbit antibodies which recognize human PARP DBD, followed by Texas red-conjugated goat antibodies to rabbit immunoglobulin IgG. Whereas no immunofluorescence was detected in 3T3 cells not incubated with MNNG, marked immunofluorescence was apparent in cells treated with the alkylating agent (data not shown). These results indicated the feasibility of using PARP DBD to detect DNA strand breaks in fixed cells.
Use of biotinylated PARP DBD
To avoid the use of antibodies to detect the PARP DBD bound to DNA strand breaks, we conjugated the bacterially expressed DBD to biotin so as to allow detection by reaction with horseradish peroxidase-conjugated streptavidin and enhanced chemiluminescence (ECL; Amersham). We first tested the modified DBD detection system in two human B cell lines that are known to undergo apoptosis via endonuclease cleavage of DNA following serum depletion, unlike normal B cells which become quiescent upon serum withdrawal (15) . Apoptosis was induced in either a B cell line immortalized with EBV in vitro (Fig. 2) or in Burkitt lymphoma-derived B cells (Fig. 3) by withdrawal of autocrine growth factor as described (15) . The occurrence of apoptosis was confirmed by a morphological assay (20) using fluorescence microscopy with a mixture of acridine orange and ethidium bromide (data not shown). The cells were then examined by phase contrast microscopy and by fluorescence microscopy with biotinylated DBD and horseradish peroxidaseconjugated streptavidin (Figs 2 and 3) . In virtually all instances, only those cells showing the morphological characteristics (cell shrinkage and nuclear condensation) of apoptosis were stained by the biotinylated PARP DBD. The number of stained cells increased with time after autocrine factor withdrawal.
We recently characterized the stages of apoptosis with respect to PARP activation, PARP proteolysis and DNA fragmentation in a human osteosarcoma cell line that undergoes a slow (8-10 days), spontaneous and reproducible death program in culture (7) . Activation of PARP occurred early, within 2 days of cell plating for apoptosis, while PARP proteolysis was detected immunocytochemically between 4 and 6 days. DNA fragmentation was not evident until 6-10 days in culture, as determined by nucleosome ladder formation. In the current study we wished to compare the sensitivity of this new methodology for detecting strand breaks, using the osteosarcoma system, to a widely used technique. We first confirmed that the osteosarcoma cells were undergoing apoptosis, as measured by apopain activity (9) . Figure 4 shows a marked increase in PARP cleavage activity by day 8. We then measured the ability of the PARP DBD to detect DNA breaks at these two time points (Fig. 5) . In both attached and floating cells, an increase in the binding of PARP DBD was observed in the late stage of apoptosis. We then tested a well-established assay for DNA strand breaks in apoptotic cells which relies upon the ability of the Klenow fragment of DNA polymerase I to incorporate nucleotides in situ (21) . We therefore measured the levels of DNA strand breaks in fixed cells by incubating the human osteosarcoma cells with Klenow enzyme in the presence of biotinylated nucleotides. Samples were analyzed from early (day 3), middle (day 6) and late (day 8) stages of apoptosis; the results of a typical experiment are shown in Figure 6 . In general, the number of osteosarcoma cell nuclei positive for in situ nucleotide incorporation also increased with time, consistent with our other assays for apopain activity and DNA strand breaks. However, fewer apoptotic nuclei were detected by the Klenow assay than by the PARP DBD assay (Figs 5 and 6 ). At day 3, none of the nuclei were stained. By day 6, several nuclei that appeared morphologically apoptotic stained positively for nucleotide incorporation. More nuclei stained positively for strand breaks by day 8, although the proportion of positive cells remained in the minority (Fig. 6 ). At this time point <30% of attached cells were Klenow-positive, compared with >80% that were DBD-positive.
DISCUSSION
Satoh and Lindahl (4, 5) recently demonstrated that unmodified PARP binds to a damaged DNA plasmid in vitro and inhibits repair in the absence of NAD. It is hypothesized that PARP cycles between an unmodified form, which blocks DNA strand ends, and a modified form, which is released from DNA, thereby allowing access of repair enzymes. Automodification of intact PARP by long chains of branched ADP-ribose polymers has in fact been shown to result in a loss of affinity of the enzyme for DNA (22) . We recently tested this model by cycling PARP in vitro with bacterially expressed deletion mutants of PARP (6) . Our data using this in vitro assay of DNA showed that those mutants that possess an intact DBD and are therefore able to bind to single-strand breaks inhibit DNA repair when added to a PARP-depleted HeLa cell extract. However, deletions in the automodification domain or the NAD binding domain prevented alleviation of the inhibition exerted by these mutants by NAD. We thus reasoned that the DBD could be used as a tool to detect DNA damage in intact cells.
The cleavage of PARP into a separate DBD that cannot be automodified also suggests the possibility that the 24 kDa cleavage product binds irreversibly to the numerous strand breaks characteristic of the final stages of apoptosis. This may account for the fact that expression of the DBD in living cells has been shown to interfere with the DNA repair function of endogenous PARP (23, 24) .
We examined the above hypotheses directly by synthesizing a recombinant peptide spanning this proteolytic fragment of PARP. We tested this new assay by measuring binding of the recombinant DBD in 3T3 cells treated with MNNG, which is known to induce strand breaks, as well as in other well-defined apoptotic systems. Immunofluorescence analysis demonstrated an increased binding of excess biotinylated PARP DBD during the later stages of apoptosis in osteosarcoma cells. This analysis was easier to perform and was at least as sensitive as an assay utilizing Klenow incorporation of biotinylated nucleotides.
In a comparison with a commonly used system based on Klenow incorporation of biotinylated nucleotides for the detection of DNA strand breaks in fixed cells, our biotinylated DBD method proved at least as sensitive (compare Figs 5 and 6 ). The differential sensitivity of the two assays may relate to several factors, including increased sensitivity of fluorescence. In addition, Klenow incorporation of biotinylated nucleotides only occurs at double-stranded DNA 5′ overhangs, but not with single-stranded DNA, double-stranded DNA with 3′-OH overhangs or double-stranded DNA with blunt ends. On the other hand, the PARP DBD binds directly to all single-stranded DNA and double-stranded DNA breaks and requires no enzyme catalysis, indicating that this a useful and simple tool for detecting apoptotic DNA breaks in situ.
